Nivolumab in Combination With High Dose Radiotherapy at Varied Tumor Sites in Advanced Melanoma and no Prior Antitumoral Treatment
Phase of Trial: Phase II
Latest Information Update: 29 Aug 2017
At a glance
- Drugs Nivolumab (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Acronyms NIRVANA
- 22 Aug 2017 Planned End Date changed from 1 Jul 2019 to 1 Nov 2020.
- 22 Aug 2017 Planned primary completion date changed from 1 Sep 2018 to 3 Mar 2019.
- 22 Aug 2017 Status changed from not yet recruiting to recruiting.